Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

The acute oral, dermal and inhalation toxicity was investigated in studies performed comparable to the relevant guidelines, resulting in an oral LD50 of 320-460 mg/kg bw, a dermal LD50 of 200-400 mg/kg bw and an inhalation LC50 of 420 mg/m3. Thus, the substance is harmful to health via the oral route and toxic via the dermal and inhalation route.

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records
Reference
Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
12 July 1978 - 26 July 1978
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
comparable to guideline study with acceptable restrictions
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 401 (Acute Oral Toxicity)
Deviations:
yes
Remarks:
The study documentation does not state whether the animals were fed or fasted, as it is often the case in pre-guideline studies. However, the described toxicity fits well into the overall toxicity profile of the test substance.
Principles of method if other than guideline:
BASF-Test
GLP compliance:
no
Remarks:
pre GLP-study
Test type:
standard acute method
Limit test:
no
Species:
rat
Strain:
Sprague-Dawley
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Weight at study initiation: males: 188 g (mean), females: 165 g (mean)



Route of administration:
oral: gavage
Vehicle:
other: 0.5% aqueous CMC
Details on oral exposure:
VEHICLE
- Concentration in vehicle: 3.16, 4.64, 6.81, 10.0 %

MAXIMUM DOSE VOLUME APPLIED: 10 mL

Doses:
316, 464, 681, 1000 mg/kg bw
No. of animals per sex per dose:
5
Control animals:
not specified
Details on study design:
- Duration of observation period following administration: 14 days
- Frequency of observations: several times on the day of exposure and daily thereafter
- Frequency of weighing: days 0, 2, 7 and 13
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight
Key result
Sex:
male/female
Dose descriptor:
LD50
Effect level:
> 320 - < 460 mg/kg bw
Mortality:
316 mg/kg bw: no mortality occurred;
464 mg/kg bw: 4 males and 3 females died within 24 h;
681 mg/kg bw: 5 males and 4 females died within 24 h;
1000 mg/kg bw: 5 males and 3 females died within 24 h, all animals died within 48 h.
Clinical signs:
other: dyspnoea, apathy, diarrhoea, poor health state, salivation, blood in stool at all dose groups reported
Gross pathology:
Gross pathology revealed reddening in stomach and gut, scattered occurrence of gastric ulcer, and diarrheic gut contents, acute dilatation of heart in animals that died. No changes were noted in organs of sacrificed animals.

Table 1: Mortality:

 Dose

(mg/kg bw)

 Gender

 Conc. %

 1 h

 24 h

 48 h

 day 7

 day 14

1000

 male

10

0/5

5/5

5/5

5/5

5/5

1000

 female

10

0/5

3/5

5/5

5/5

5/5

681

 male

6.81

0/5

5/5

5/5

5/5

5/5

681

 female

6.81

0/5

4/5

4/5

4/5

4/5

464

 male

4.64

0/5

4/5

4/5

4/5

4/5

464

 female

4.64

0/5

3/5

3/5

3/5

3/5

316

 male

3.16

0/5

0/5

0/5

0/5

0/5

316

female 

3.16

0/5

0/5

0/5

0/5

0/5 

Interpretation of results:
Category 4 based on GHS criteria
Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
LD50
Value:
320 mg/kg bw
Quality of whole database:
similar to OECD TG 401

Acute toxicity: via inhalation route

Link to relevant study records
Reference
Endpoint:
acute toxicity: inhalation
Type of information:
experimental study
Adequacy of study:
key study
Study period:
22 May 1979
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
comparable to guideline study with acceptable restrictions
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 403 (Acute Inhalation Toxicity)
Deviations:
yes
Remarks:
concentration was measured, but not humidity, temperature and particle size.
Principles of method if other than guideline:
BASF-Test
GLP compliance:
no
Test type:
fixed concentration procedure
Limit test:
no
Species:
rat
Strain:
Sprague-Dawley
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: WIGA, Sulzfeld and MUS RATTUS, Brunnthal, Germany
- Weight at study initiation: 185±15 g (mean)
- Diet: Herilan MRH (H. EGGERSMANN KG) ad libitum
- Water: tap water ad libitum

Route of administration:
inhalation: aerosol
Type of inhalation exposure:
nose/head only
Remarks:
dynamic method
Vehicle:
other: unchanged (no vehicle)
Analytical verification of test atmosphere concentrations:
yes
Remarks:
gas chromatography
Duration of exposure:
4 h
Concentrations:
0.053, 0.31, 0.41, 0.62 mg/L (analytical concentration) [0.31, 1.41, 1.83, 2.13 mg/L (nominal concentration)]
No. of animals per sex per dose:
10
Control animals:
not specified
Details on study design:
- Duration of observation period following administration: 14 days
- Frequency of observations: daily
- Frequency of weighing: days 0, 7 and 14
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight
Statistics:
Statistical evaluation included a probit analysis accordinmg to D.J. Finney.
Key result
Sex:
male/female
Dose descriptor:
LC50
Effect level:
0.42 mg/L air (analytical)
Exp. duration:
4 h
Sex:
male
Dose descriptor:
LC50
Effect level:
0.44 mg/L air (analytical)
Exp. duration:
4 h
Sex:
female
Dose descriptor:
LC50
Effect level:
0.4 mg/L air (analytical)
Exp. duration:
4 h
Mortality:
0.62 mg/L air: 9/10 (males); 10/10 (females)
0.41 mg/L air: 3/10 (males); 5/10 (females)
0.31 mg/L air: 2/10 (males); 1/10 (females)
0.053 mg/L air: 0/10 (males); 0/10 (females)
Clinical signs:
other: Animals showed apathy, staggering, squatting and abdominal position, ruffled fur and in general clinical symptoms that were indicative of a marked irritant effect on the airways and eyes such as eyelid closure, watery eye and nose discharge and corneal op
Body weight:
Some retardation in body weight gain was observed in the treated animals during the post observation. However, there was no clear dose-response and body weights were not statistically significantly different from control at the end of the postobservation period.
Gross pathology:
Animals that died:
heart: acute dilatation of the right ventricle, acute congestive hyperemia;
lungs: focal hyperemia, additional moderate edema;

Sacrificed animal: no pathologic findings noted.

Test concentrations and mortality:

Dose (mg/L)   male  female
 0.62  9/10  10/10
 0.41  3/10  5/10
0.31  2/10  1/10
 0.053  0/10  0/10

Body weight:

Mean body weight (in g)   male        female     
   0 days  7 days  14 days  0 days  7 days  14 days
0.62 mg/L 189 (10) 196 (1) 233 (1) 178 (10) - -
0.41 mg/L 180 (10) 166 (7) 233 (7) 177 (10) 188 (5) 209 (5)
0.31 mg/L 181 (10) 189 (8) 234 (8) 184 (10) 185 (9) 198 (9)
0.053 mg/L 190 (10) 202 (10) 240 (10) 184 (10) 189 (10) 203 (10)
control 182 (10) 220 (10) 253 (10) 175 (10) 182 (10) 194 (10)

(): number of animals;

"-": all animals dead.

Interpretation of results:
Category 2 based on GHS criteria
Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
LC50
Value:
420 mg/m³ air
Quality of whole database:
similar to OECD TG 403

Acute toxicity: via dermal route

Link to relevant study records
Reference
Endpoint:
acute toxicity: dermal
Type of information:
experimental study
Adequacy of study:
key study
Study period:
7 September 1978 - 16 November 1978
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
comparable to guideline study with acceptable restrictions
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 402 (Acute Dermal Toxicity)
Deviations:
yes
Remarks:
two dose levels; scarce study report omitts details of test conditions which are, however, contained in raw data.
Principles of method if other than guideline:
BASF-Test
GLP compliance:
no
Test type:
standard acute method
Limit test:
yes
Species:
rabbit
Strain:
Vienna White
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Weight at study initiation: males: 2.95 kg; females: 3.1 kg
- Diet: SNIFF, ad libitum

Type of coverage:
occlusive
Vehicle:
unchanged (no vehicle)
Details on dermal exposure:
TEST SITE
- Area of exposure: 50 cm² (200 mg/kg bw) and 45 - 102 cm² (400 mg/kg bw)

REMOVAL OF TEST SUBSTANCE
- Washing: After the application time the skin was washed with water/Lutrol (1:1)
- Time after start of exposure: 24 h

Duration of exposure:
24 h
Doses:
200, 400 mg/kg bw
No. of animals per sex per dose:
5
Control animals:
not specified
Details on study design:
- Duration of observation period following administration: 8 days
- Frequency of observations: daily
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs
Key result
Sex:
male/female
Dose descriptor:
LD50
Effect level:
> 200 - < 400 mg/kg bw
Mortality:
400 mg/kg bw: After day 7 4/5 males and 5/5 female rabbits died and mortality ocurred mainly within the first 24 hours.
200 mg/kg bw: None of the 5 male rabbits died and 3/5 females died within 24 hours.
Clinical signs:
other: Systemic toxicity: cyanosis, apathy, dyspnea, accelerated breathing, abdominal position with flaccid extremities, lateral position, trembling. Local irritations: All animals showed formation of soft necrosis after removal of dressing. The surviving animal
Gross pathology:
Animals that died:
Heart: acutely dilated, right; acute congestion;
Lungs: notable congestion, in some animals edematized;
Liver: gray-white lobular periphery broader.

Table 1: Mortality

 Dose (mg/kg bw)  Gender  1 h  24 h  48 h  7 days 14 days 
 200  male  0/5  0/5  0/5 0/5  0/5
 200  female  0/5  3/5  3/5  3/5  3/5
 400  male  0/5  3/5  3/5  4/5  4/5
 400  female  0/5  5/5  5/5  5/5  5/5
Interpretation of results:
Category 3 based on GHS criteria
Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
LD50
Value:
200 mg/kg bw
Quality of whole database:
similar to OECD TG 402

Additional information

oral

In a study comparable to OECD TG 401, 5 male and 5 female rats per group were dosed with 316; 464; 681 or 1000 mg/kg bw in 0.5 % aqueous carboxymethylcellulose preparation. While complete mortality was observed at the highest dose level, mortality rates in the mid dose groups were 90 respectively 70 % and no rats died when treated with 316 mg/kg bw. Clinical symptoms were unspecific (BASF AG 1979a). The LD50 rat was 320-460 mg/kg bw.

inhalation

In a study similar OECD TG 403, 10 rats per sex and dose group were exposed to analytical aerosol concentrations of 53; 310; 410 or 620 mg/m3. While 9 males and 10 females died at the highest concentration, mortality rates in the mid dose groups were 40 resp. 15%. No rats died at the lowest concentration. The LC50 rat (inhalation, liquid aerosol) was 420 mg/m3/4h (BASF AG 1979b).

A supporting report stated that as a result of exposure of rats to saturated test item atmosphere (concentration not given) at 20°C for 4 or 8 hours, 1/6 animals died after 8 h exposure (BASF AG, 1957).

dermal

In a study similar to OECD TG 402 necrotic skin changes at the application site were reported when 5 animals per sex and per dose group treated with the undiluted test substance were examined. While 4 males and 5 females died when treated with 400 mg/kg bw, none of the males and 3 females died when treated with 200 mg/kg bw. The LD50 rabbit was 200-400 mg/kg bw (BASF AG 1979c).

Furthermore, there a several other acute oral, dermal as well as inhalative toxicity studies on different species available, which were not considered for hazard assessment due to their weak reliability (reliability 3, not reliable).

Justification for classification or non-classification

Classification, Labeling, and Packaging Regulation (EC) No 1272/2008

2,2'-dimethyl-4,4'-methylenebis(cyclohexylamine) is listed in Annex VI of Regulation (EC) No 1272/2008 with cat. 3 for acute dermal and inahaltion (H311 and H 331) and cat. 4 (H302) for acute oral expsoure as a minimum classification. However, the available data for acute toxicity are reliable and suitable for classification purposes under Annex I of Regulation (EC) No 1272/2008. Based on these data, 2,2'-dimethyl-4,4'-methylenebis(cyclohexylamine) is considered to be classified for acute oral toxicity cat. 4 (H302), acute inhalation toxicity cat. 2 (H330) and for acute dermal toxicity cat. 3 (H311) under Regulation (EC) No 1272/2008, as amended for the twelfth time in Regulation (EU) 2019/521.